Why is any technology killed off? It's been superseded - either on price or performance or both.
According to Genomeweb, Illumina had 66% of the market in 2012:
http://www.genomeweb.com/sequencing/...-desktop-share
Roche's share was 8% at this point.
I think you may have been a bit misled on their market penetration post PGM and post-MiSeq
-
{Discussion}Roche stop supporting the 454 platform by mid-2016
Hi, I am a graduate student and I have just heard Roche stop supporting the 454 pyrosequencing platform by 2016. Our university has to buy another Next-gen sequencing platform.
I was surprised. Does anyone know what happened? Two year ago, I think 454 pyrosequencing occupied >50% market. I don't think this is about business. Also, lots of publications use pyrosequencing
Are they gonna develop new sequencing technologies? Is pyrosequencing a technological dead end? Is Illumina a good choice?
Ben
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Today, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM
Leave a comment: